New drug trial targets debilitating fatigue in mitochondrial disease
Symptom relief
Recruiting now
This study is testing whether an investigational drug called KL1333 can reduce fatigue and improve leg strength and endurance in adults with primary mitochondrial disease. About 180 participants will take either KL1333 or a placebo pill twice daily for 48 weeks, with neither the …
Phase: PHASE2 • Sponsor: Abliva AB • Aim: Symptom relief
Last updated Mar 25, 2026 14:09 UTC